Results 241 to 250 of about 43,472 (345)
Pollutant‐induced epithelial damage also leads to a cascade of harmful effects, including reduced mucus secretion, decreased luminal pH, and enhanced absorption of toxins. These changes contribute to oxidative stress (↑ malondialdehyde (MDA); ↓ superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx), and heightened ...
Meysam Zarezadeh Ph.D. +5 more
wiley +1 more source
Alternating reconstruction and registration for digital breast tomosynthesis [PDF]
Arridge, S +4 more
core
Synchronous primary gallbladder squamous cell carcinoma and colon adenocarcinoma: A case report and literature review. [PDF]
Shin MH, Kim YH, Lim SC, Lim SC.
europepmc +1 more source
Primary Malignant Melanoma of the Lung With a Long‐Term Course: A Case Report
A 66‐year‐old man with a 20‐year history of recurrent haemoptysis presented with mild bronchiectasis and linear opacities detected on chest computed tomography (CT), and the lesion was followed up annually and gradually enlarged into a mass over 10 years.
Yusei Fukushima +7 more
wiley +1 more source
Proliferation-Based WHO Grading and Heterogeneous Gastrin Expression in Canine Gallbladder Neuroendocrine Tumors. [PDF]
Wu YT +7 more
europepmc +1 more source
GLP‐1 receptor agonists are generally effective in weight loss and improvement in metabolic markers. They are well tolerated in patients with inflammatory bowel disease, with observational evidence showing no increased risk of disease exacerbation and possible signals of reduced steroid use, hospitalization, and surgery. ABSTRACT Background Obesity and
Brooke Maracle +8 more
wiley +1 more source
Multifocal Biliary Adenoma Involving the Gallbladder and Common Bile Duct Presenting With Obstructive Jaundice: A Case Report. [PDF]
Guadarrama A +5 more
europepmc +1 more source
Radionuclide therapy using PD‐K(225Ac‐DOTA)‐RGD in BxPC‐3‐bearing mice. PD‐K(225Ac‐DOTA)‐RGD successfully suppressed tumor growth. ABSTRACT Improved peptide pharmacokinetics are needed to enhance the therapeutic effects of peptide‐based radionuclide therapy.
Mitsuyoshi Yoshimoto +5 more
wiley +1 more source

